Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,417.57
+8.19 (0.58%)
At close: Nov 4, 2026, 4:00 PM EST
1,417.18
-0.39 (-0.03%)
After-hours: Nov 4, 2026, 6:16 PM EST
Eli Lilly Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 86,462 | 65,179 | 45,043 | 34,124 | 28,541 | 28,318 |
Revenue Growth | 45.51% | 44.70% | 32.00% | 19.56% | 0.79% | 15.40% |
Gross Profit Gross Profit Growth | 72,312 | 54,127 | 36,625 | 27,042 | 21,912 | 21,345 |
Operating Income Operating Income Growth | 44,315 | 29,696 | 17,040 | 10,325 | 8,653 | 8,273 |
Net Income Net Income Growth | 27,580 | 20,640 | 10,590 | 5,240 | 6,245 | 5,582 |
Earnings Per Share EPS Growth | 30.81 | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 |
EPS Growth | 50.73% | 95.99% | 101.90% | -15.94% | 12.75% | -9.87% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Baqsimi Baqsimi Growth | - | - | 29.1 | 677.6 | 139.3 | 113.2 |
Basaglar Basaglar Growth | 638 | 626 | 676.9 | 728.3 | 760.4 | 892.5 |
Humalog Humalog Growth | 1,974 | 2,168 | 2,325 | 1,663 | 2,061 | 2,453 |
Humulin Humulin Growth | 657 | 705 | 917.1 | 852.1 | 1,019 | 1,223 |
Jardiance Jardiance Growth | 4,692 | 3,432 | 3,341 | 2,745 | 2,066 | 1,491 |
Mounjaro Mounjaro Growth | 36,737 | 22,965 | 11,540 | 5,163 | 482.5 | - |
Trajenta Trajenta Growth | 266 | 318 | 353.9 | 386.9 | 383.7 | 372.5 |
Trulicity Trulicity Growth | 4,079 | 4,276 | 5,254 | 7,133 | 7,440 | 6,472 |
Zepbound Injectable Zepbound Injectable Growth | 18,701 | 13,542 | 4,926 | 175.8 | - | - |
Other Cardiometabolic Health Other Cardiometabolic Health Growth | 344 | 189 | 187.9 | 143.1 | 80.8 | 121.2 |
Oncology Oncology Growth | 10,045 | 9,376 | 8,752 | 6,658 | 5,666 | 5,741 |
Immunology Immunology Growth | 5,596 | 5,247 | 4,393 | 3,798 | 3,345 | 3,361 |
Neuroscience Neuroscience Growth | 1,715 | 1,391 | 1,473 | 2,879 | 1,546 | 1,899 |
Other Product Other Product Growth | 738 | 944 | 903 | 1,122 | 3,520 | 4,130 |
Revenue (Total) Revenue (Total) Growth | 86,462 | 65,179 | 45,043 | 34,124 | 28,541 | 28,318 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5,645 | 7,491 | 3,754 | 3,753 | 3,126 | 5,193 |
Total Debt Total Debt Growth | 49,503 | 43,865 | 34,791 | 26,465 | 16,373 | 16,927 |
Net Cash (Debt) Net Cash Growth | -43,858 | -36,374 | -31,037 | -22,712 | -13,247 | -11,733 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -48.99 | -40.45 | -34.33 | -25.14 | -14.64 | -12.87 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 30,645 | 16,813 | 8,818 | 4,240 | 7,586 | 7,366 |
Capital Expenditures CapEx Growth | -10,984 | -7,841 | -5,058 | -3,448 | -1,854 | -1,310 |
Free Cash Flow Free Cash Flow Growth | 19,661 | 8,972 | 3,760 | 792 | 5,731 | 6,056 |
Free Cash Flow Growth | 112.05% | 138.62% | 374.75% | -86.18% | -5.36% | 18.48% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 83.63% | 83.04% | 81.31% | 79.25% | 76.77% | 75.38% |
Operating Margin | 51.25% | 45.56% | 37.83% | 30.26% | 30.32% | 29.21% |
Pretax Margin | 40.21% | 39.48% | 28.15% | 19.21% | 23.85% | 21.74% |
Profit Margin | 31.90% | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% |
FCF Margin | 22.74% | 13.76% | 8.35% | 2.32% | 20.08% | 21.39% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 6.920 | 6.000 | 5.200 | 4.520 | 3.920 | 3.400 |
Dividend Per Share Growth | 15.33% | 15.38% | 15.04% | 15.31% | 15.29% | 14.87% |
Dividend Yield | 0.49% | 0.56% | 0.67% | 0.78% | 1.01% | 1.23% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 46.01 | 46.62 | 65.64 | 100.04 | 55.66 | 44.86 |
Forward PE | 30.14 | 34.33 | 35.13 | 53.37 | 46.27 | 31.77 |
P/FCF Ratio | 64.38 | 107.25 | 184.88 | 661.90 | 60.65 | 41.35 |
PS Ratio | 14.64 | 14.76 | 15.43 | 15.36 | 12.18 | 8.84 |